These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 33578261)
61. Apilarnil exerts neuroprotective effects and alleviates motor dysfunction by rebalancing M1/M2 microglia polarization, regulating miR-155 and miR-124 expression in a rotenone-induced Parkinson's disease rat model. Salama RM; Darwish SF; Yehia R; Eissa N; Elmongy NF; Abd-Elgalil MM; Schaalan MF; El Wakeel SA Int Immunopharmacol; 2024 Aug; 137():112536. PubMed ID: 38909495 [TBL] [Abstract][Full Text] [Related]
62. Mechanistic evaluation of Ursolic acid against rotenone induced Parkinson's disease- emphasizing the role of mitochondrial biogenesis. Peshattiwar V; Muke S; Kaikini A; Bagle S; Dighe V; Sathaye S Brain Res Bull; 2020 Jul; 160():150-161. PubMed ID: 32147532 [TBL] [Abstract][Full Text] [Related]
63. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. Inden M; Kitamura Y; Takeuchi H; Yanagida T; Takata K; Kobayashi Y; Taniguchi T; Yoshimoto K; Kaneko M; Okuma Y; Taira T; Ariga H; Shimohama S J Neurochem; 2007 Jun; 101(6):1491-1504. PubMed ID: 17459145 [TBL] [Abstract][Full Text] [Related]
64. Neuroprotective effect of agmatine (decarboxylated l-arginine) against oxidative stress and neuroinflammation in rotenone model of Parkinson's disease. El-Sayed EK; Ahmed A; Morsy EE; Nofal S Hum Exp Toxicol; 2019 Feb; 38(2):173-184. PubMed ID: 30001633 [TBL] [Abstract][Full Text] [Related]
66. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Zaitone SA; Abo-Elmatty DM; Elshazly SM Indian J Pharmacol; 2012; 44(6):774-9. PubMed ID: 23248410 [TBL] [Abstract][Full Text] [Related]
67. Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model. Hedya SA; Safar MM; Bahgat AK Mol Neurobiol; 2018 Sep; 55(9):7579-7587. PubMed ID: 29429051 [TBL] [Abstract][Full Text] [Related]
68. Effect of montelukast in experimental model of Parkinson's disease. Nagarajan VB; Marathe PA Neurosci Lett; 2018 Aug; 682():100-105. PubMed ID: 29885451 [TBL] [Abstract][Full Text] [Related]
69. Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico& in vivo anti-Parkinson's disease study. Kamal RE; Menze E; Albohy A; Ahmed HI; Azab SS Eur J Pharmacol; 2022 Oct; 932():175204. PubMed ID: 35964655 [TBL] [Abstract][Full Text] [Related]
70. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Alam M; Danysz W; Schmidt WJ; Dekundy A Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571 [TBL] [Abstract][Full Text] [Related]
71. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease. Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691 [TBL] [Abstract][Full Text] [Related]
72. Neuroprotective effect of Valeriana wallichii rhizome extract against the neurotoxin MPTP in C57BL/6 mice. Sridharan S; Mohankumar K; Jeepipalli SP; Sankaramourthy D; Ronsard L; Subramanian K; Thamilarasan M; Raja K; Chandra VK; Sadras SR Neurotoxicology; 2015 Dec; 51():172-83. PubMed ID: 26522450 [TBL] [Abstract][Full Text] [Related]
73. Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor. Mansour HM; Mohamed AF; Khattab MM; El-Khatib AS Brain Res; 2024 Jul; 1834():148893. PubMed ID: 38554797 [TBL] [Abstract][Full Text] [Related]
74. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. Concannon RM; Okine BN; Finn DP; Dowd E Exp Neurol; 2016 Sep; 283(Pt A):204-12. PubMed ID: 27317300 [TBL] [Abstract][Full Text] [Related]
75. Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson's disease. Zhang Q; Chen S; Yu S; Qin J; Zhang J; Cheng Q; Ke K; Ding F Neuropharmacology; 2016 Sep; 108():238-51. PubMed ID: 27108097 [TBL] [Abstract][Full Text] [Related]
76. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Nehru B; Verma R; Khanna P; Sharma SK Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296 [TBL] [Abstract][Full Text] [Related]
77. Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in mouse model of Parkinson's disease. Khatri DK; Juvekar AR Pharmacol Biochem Behav; 2016; 150-151():39-47. PubMed ID: 27619637 [TBL] [Abstract][Full Text] [Related]
78. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572 [TBL] [Abstract][Full Text] [Related]
79. Anti-inflammatory, anti-apoptotic, and neuroprotective potentials of anethole in Parkinson's disease-like motor and non-motor symptoms induced by rotenone in rats. Moradi Vastegani S; Khoshnam SE; Mansouri E; Ghafouri S; Bakhtiari N; Farbood Y; Sarkaki A Metab Brain Dis; 2023 Aug; 38(6):2159-2174. PubMed ID: 37204660 [TBL] [Abstract][Full Text] [Related]
80. Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease. Aksoy D; Solmaz V; Çavuşoğlu T; Meral A; Ateş U; Erbaş O Am J Med Sci; 2017 Sep; 354(3):319-324. PubMed ID: 28918840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]